FeesSafety
Pluang+

Piper Sandler upgrades Medtronic on growth from acquisitions and new treatments.

Analyst Insights
17 Nov 2026, 17:06 WIB
Alex Lavoie
View Source
Bullish
Piper Sandler upgrades Medtronic on growth from acquisitions and new treatments.

Piper Sandler upgraded Medtronic to Overweight with a $120 price target, citing strategic growth through acquisitions and product launches in vascular, heart rhythm, and robotic surgery. Medtronic's recent acquisition of Contego Medical expands its carotid disease treatment portfolio, while CMS coverage for its Symplicity Spyral renal denervation opens access to over 18 million U.S. patients. The company’s Hugo robotic surgery platform has also gained initial U.S. clearance, positioning Medtronic for future growth. This upgrade reflects confidence in Medtronic’s expanding market presence and revenue potential.

Medtronic shares are trading at USD 103.51 on Pluang, showing a 0.61% increase as of Nov 17, 2026 18:51 WIB. The stock has a dividend yield of 2.8% and a market cap of $131.60 billion at this time.

More News (MDT)

banner-footerbanner-footer

Invest & Trade with
#1 Award-Winning Investment Super App